Neonatal lupus erythematosus – prevention is better
than cure

Agata Liszewska; Anna Woźniacka

doi:10.5114/ada.2022.122601

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2022
vol. 39

Send email

Copy url:

abstract:

Review paper

Neonatal lupus erythematosus – prevention is better than cure

Agata Liszewska

¹

,

Anna Woźniacka

¹

Department of Dermatology and Venereology, Medical University of Lodz, Lodz, Poland

Adv Dermatol Allergol 2022; XXXIX (6): 1021-1026

DOI: https://doi.org/10.5114/ada.2022.122601

Online publish date: 2022/12/22

View full text Get citation

Neonatal lupus erythematosus (NLE) is a congenital autoimmune condition in which the transplacental passage of immunoglobulin G (IgG) directed against auto-antigens causes clinical symptoms in the foetus or neonate. Anti-Ro/SS-A, anti-La/SS-B, and to a lesser extent, anti-U1RNP autoantibodies (aAbs) have the strongest association with NLE. However, ~ 50% of affected mothers are asymptomatic despite carrying those aAbs. The clinical picture of the disease is very diverse. Cardiac manifestations are the most severe, including congenital heart block (CHB), with a mortality rate of ~18%. Preventative therapy with hydroxychloroquine (HCQ) reduces the recurrence rate of CHB in subsequent pregnancies by ~50%.

keywords:

Neonatal lupus erythematosus – prevention is better than cure

Agata Liszewska 1 , Anna Woźniacka 1

neonatal lupus erythematosus, congenital heart block, antinuclear antibodies, anti-Ro/SSA antibodies, anti-La/SSB antibodies

Agata Liszewska

¹

,

Anna Woźniacka

¹